Cognitive Function clinical trials

Explore recruiting cognitive function clinical trials.

Recruiting cognitive function studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cognitive Function trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy (FLEET): A Randomized Controlled Trial

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Cognitive function after liver transplantation comparing Tacrolimus formulations

Germany

Therapeutic use (Phase IV) EU CTIS Study details

A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)

Spain, Germany, Italy, Sweden, France, Luxembourg

Therapeutic exploratory (Phase II) EU CTIS Study details

Cognitive Function, Depression, Anxiety, and Quality of Life in Chronic Heart Failure Patients with Iron Deficiency with and without Anaemia: Effects of Intravenous Iron (Ferric Derisomaltose) CogFer-HF Study

Germany

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome

Netherlands, Spain, Germany, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Prospective evaluation of potential effects of repeated gadolinium-based contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group—ODYSSEY

Italy, Germany, France

Therapeutic use (Phase IV) EU CTIS Study details

Cognitive Function trials by city

Cognitive Function in Toronto Cognitive Function in Vancouver Cognitive Function in Montreal Cognitive Function in Calgary Cognitive Function in Edmonton Cognitive Function in Ottawa Cognitive Function in Winnipeg Cognitive Function in Quebec City Cognitive Function in Hamilton Cognitive Function in Kitchener Cognitive Function in London Cognitive Function in Halifax Cognitive Function in New York Cognitive Function in Los Angeles Cognitive Function in Chicago Cognitive Function in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease